Search for a trial

1 results

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel
Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer*s Disease

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-511610-20-00 check the CTIS register for the current data. Cognitive and functional abilities will be evaluated using psychometric scales (ie, cognitive subscale of the Alzheimer*s Disease…

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer*s Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel
Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer*s Disease